

Health State Utilities of Patients with Heart Failure: A Systematic Literature Review

Gian Luca Di Tanna, Michael Urbich, Heidi S. Wirtz, Barbara Potrata, Marieke Heisen, Craig Bennison, John Brazier, Gary Globe

Correspondence to: Gian Luca Di Tanna, The George Institute for Global Health. Level 5, 1 King St. Newtown NSW 2042 Australia; Telephone: +61 2 8052 4606; Email address: gditanna@georgeinstitute.org.au

Online Resource 3. Quality Assessment of the studies based on relevant criteria from the Papaioannou et al. 2013 checklist

Author and publication year	Response rates reported	Response rates likely threat to validity	Reported loss to follow-up	Reasons for the loss to follow-up given	Reasons for the loss to follow-up threat to the validity	Missing data reported	Methods to deal with missing data given	Missing data threat to the validity	Country patients match those modelled	Population characteristics match those modelled	The use of generic preference-based instrument (preferably EQ-5D)	Change in HRQoL undertaken directly from the patients	Valuation of changes undertaken from general population	Choice-based methods used to value the health states
Alehagen 2008 ¹	Y	N	NA	NA	NA	N	N	U	Y	Y	N	Y	N	Y
Alva 2014 ²	Y	N	N	N	U	N	N	U	Y	Y	Y	Y	Y	Y
Ambrosy 2016 ³	Y	Y	N	N	U	N	N	U	Y	Y	Y	Y	N	Y
Andreae 2018 ⁴	Y	N	NA	NA	NA	N	N	U	Y	Y	Y	Y	N	Y
Austin 2005 ⁵	Y	N	N	N	U	N	N	U	Y	Y	Y	Y	N	Y
Austin 2008 ⁶	N	U	N	N	U	Y	N	N	Y	Y	Y	Y	N	Y
Austin 2009 ⁷	N	U	N	N	U	Y	N	N	Y	Y	Y	Y	N	Y
Berg 2010 ⁸	Y	N	Y	N	U	N	N	U	Y	Y	Y	Y	N	Y
Berg 2015 ⁹	Y	N	Y	N	U	N	N	U	Y	Y	Y	Y	N	Y

Author and publication year	Response rates reported	Response rates likely threat to validity	Reported loss to follow-up	Reasons for the loss to follow-up given	Reasons for the loss to follow-up threat to the validity	Missing data reported	Methods to deal with missing data given	Missing data threat to the validity	Country patients match those modelled	Population characteristics match those modelled	The use of generic preference-based instrument (preferably EQ-5D)	Change in HRQoL undertaken directly from the patients	Valuation of changes undertaken from general population	Choice-based methods used to value the health states
Berg 2017 ¹⁰	Y	N	NA	NA	NA	Y	N	U	Y	Y	Y	Y	U	Y
Boros 2012 ¹¹	Y	N	NA	NA	NA	N	N	U	Y	Y	Y	Y	Y	Y
Briggs 2017 ¹²	Y	N	N	N	U	N	N	U	Y	Y	Y	Y	N	Y
Calvert 2005 ¹³	Y	U	N	N	U	Y	N	U	Y	Y	Y	Y	N	Y
Calvert 2005 ¹⁴	Y	U	N	N	U	N	Y	N	Y	Y	Y	Y	N	Y
Clark 2015 ¹⁵	Y	N	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y	Y
Clarke 2002 ¹⁶	Y	N	N	N	U	N	N	U	Y	Y	Y	N	Y	Y
Coffey 2002 ¹⁷	Y	N	NA	NA	NA	Y	Y	N	Y	Y	Y	Y	N	Y
Davies 2015 ¹⁸	Y	N	NA	NA	NA	N	N	U	Y	Y	N	N	N	Y
Delgado 2014 ¹⁹	N	NA	Y	Y	U	N	N	U	Y	N	Y	Y	N	Y
Emin 2016 ²⁰	N	U	NA	NA	NA	N	N	U	Y	Y	Y	Y	N	Y
Eurich 2006 ²¹	Y	N	N	N	U	Y	Y	N	Y	Y	Y	Y	U	Y
Feeny 2012 ²²	Y	N	N	N	U	Y	Y	N	Y	Y	Y	Y	Y	Y
Feldman 2005 ²³	Y	U	Y	Y	N	N	N	U	Y	Y	N	Y	N	Y
Ferrer 2015 ²⁴	Y	U	Y	Y	N	Y	Y	N	Y	Y	Y	Y	N	Y
Filippatos 2017 ²⁵	Y	Y	Y	N	U	N	Y	N	Y	Y	Y	Y	N	Y
Gohler 2009 ²⁶	Y	N	N	N	U	N	N	U	Y	Y	Y	Y	Y	Y
González-Guerrero 2018 ²⁷	N	U	Y	Y	N	N	N	U	Y	Y	Y	Y	Y	Y
Griffiths 2014 ²⁸	N	U	Y	N	U	Y	N	U	Y	N	Y	Y	N	Y
Griffiths 2017 ²⁹	Y	U	Y	N	U	N	N	U	Y	Y	Y	Y	Y	Y

Author and publication year	Response rates reported	Response rates likely threat to validity	Reported loss to follow-up	Reasons for the loss to follow-up given	Reasons for the loss to follow-up threat to the validity	Missing data reported	Methods to deal with missing data given	Missing data threat to the validity	Country patients match those modelled	Population characteristics match those modelled	The use of generic preference-based instrument (preferably EQ-5D)	Change in HRQoL undertaken directly from the patients	Valuation of changes undertaken from general population	Choice-based methods used to value the health states
Gutzwiller 2013 ³⁰	Y	N	N	N	U	Y	Y	N	Y	Y	Y	Y	N	Y
Havranek 1999 ³¹	Y	N	NA	NA	NA	N	N	U	Y	Y	N	Y	N	Y
Havranek 2004 ³²	Y	U	NA	NA	NA	N	N	U	Y	Y	N	Y	N	Y
Hayes 2016 ³³	Y	N	N	N	U	N	N	U	Y	Y	Y	Y	Y	Y
Herbert 2008 ³⁴	N	U	Y	N	U	Y	Y	N	Y	Y	Y	Y	N	Y
Holland 2007 ³⁵	Y	U	Y	Y	N	N	N	U	Y	Y	Y	Y	N	Y
Holland 2010 ³⁶	Y	U	Y	N	U	N	N	U	Y	Y	Y	Y	N	Y
Holst 2007 ³⁷	N	U	Y	Y	U	Y	Y	N	Y	Y	Y	Y	N	Y
Hwang 2018 ³⁸	N	U	Y	Y	U	Y	Y	U	Y	Y	Y	Y	Y	Y
Iqbal 2010 ³⁹	Y	N	NA	NA	NA	N	N	U	Y	Y	Y	Y	N	Y
Jackson 2018 ⁴⁰	Y	U	NA	NA	NA	Y	Y	N	Y	Y	Y	Y	N	Y
Janssen 2011 ⁴¹	Y	Y	NA	NA	NA	Y	Y	N	Y	Y	Y	Y	N	Y
Jolly 2009 ⁴²	Y	N	Y	N	U	Y	Y	N	Y	Y	Y	Y	N	Y
Kaplan 2011 ⁴³	Y	U	Y	N	U	N	N	U	Y	Y	Y	Y	U	Y
Kavanagh 1996 ⁴⁴	N	U	N	N	U	N	N	U	Y	Y	N	Y	N	Y
Kimura 2017 ⁴⁵	Y	U	Y	Y	U	N	N	U	Y	Y	Y	Y	Y	Y
Kirsch 2000 ⁴⁶	Y	Y	NA	NA	NA	N	N	U	Y	Y	N	Y	Y	Y
Kontodimopoulos 2011 ⁴⁷	Y	N	NA	NA	NA	N	N	U	Y	Y	Y	Y	U	Y
Kraai 2013 ⁴⁸	Y	U	NA	NA	NA	N	N	U	Y	Y	Y	Y	N	Y
Kularatna 2017 ⁴⁹	Y	U	N	N	U	N	N	U	Y	Y	Y	Y	Y	Y

Author and publication year	Response rates reported	Response rates likely threat to validity	Reported loss to follow-up	Reasons for the loss to follow-up given	Reasons for the loss to follow-up threat to the validity	Missing data reported	Methods to deal with missing data given	Missing data threat to the validity	Country patients match those modelled	Population characteristics match those modelled	The use of generic preference-based instrument (preferably EQ-5D)	Change in HRQoL undertaken directly from the patients	Valuation of changes undertaken from general population	Choice-based methods used to value the health states
Lewis 2001 ⁵⁰	Y	N	NA	NA	NA	N	N	U	Y	Y	N	Y	N	Y
Lewis 2014 ⁵¹	Y	Y	Y	N	N	N	N	U	Y	Y	Y	Y	N	Y
Li 2013 ⁵²	Y	U	N	N	U	N	N	U	Y	Y	Y	Y	N	Y
Luo 2011 ⁵³	Y	N	NA	NA	NA	N	N	U	Y	Y	Y	Y	Y	Y
Matza 2015 ⁵⁴	Y	U	NA	NA	NA	N	N	U	Y	Y	N	N	NA	Y
Maxwell 2009 ⁵⁵	N	U	NA	NA	NA	Y	Y	N	Y	Y	Y	Y	Y	Y
Mondor 2016 ⁵⁶	N	U	NA	NA	NA	N	Y	U	Y	Y	Y	Y	N	Y
Moskowitz 1997 ⁵⁷	Y	N	Y	N	U	Y	Y	Y	Y	Y	N	Y	N	Y
Muggah 2013 ⁵⁸	N	U	NA	NA	NA	Y	N	U	Y	Y	Y	Y	NA	Y
Nauck 2019 ⁵⁹	N	U	Y	Y	N	Y	Y	N	Y	Y	Y	Y	N	Y
Noyes 2009 ⁶⁰	Y	N	Y	Y	U	Y	Y	Y	Y	Y	Y	Y	Y	Y
Peters 2014 ⁶¹	Y	U	Y	N	U	Y	N	U	Y	Y	Y	Y	Y	Y
Pickard 2013 ⁶²	Y	U	NA	NA	NA	Y	Y	N	Y	Y	N	Y	N	Y
Pisa 2015 ⁶³	N	U	Y	N	N	N	N	U	Y	Y	Y	Y	NA	Y
Pressler 2011 ⁶⁴	N	U	Y	Y	N	Y	N	U	Y	Y	Y	Y	N	Y
Reed 2013 ⁶⁵	Y	N	N	N	U	N	N	U	Y	Y	Y	Y	Y	Y
Roalfe 2012 ⁶⁶	Y	N	NA	NA	NA	Y	Y	N	Y	Y	Y	Y	N	Y
Sanchez 2010 ⁶⁷	Y	N	N	N	U	N	N	U	Y	Y	Y	Y	N	Y
Shao 2019 ⁶⁸	N	U	N	N	U	N	N	U	Y	N	Y	Y	N	Y
Shephard 1998 ⁶⁹	Y	U	NA	NA	NA	N	N	U	Y	Y	N	Y	N	Y
Spertus 2005 ⁷⁰	Y	U	Y	Y	U	N	N	U	Y	Y	Y	Y	N	Y

Author and publication year	Response rates reported	Response rates likely threat to validity	Reported loss to follow-up	Reasons for the loss to follow-up given	Reasons for the loss to follow-up threat to the validity	Missing data reported	Methods to deal with missing data given	Missing data threat to the validity	Country patients match those modelled	Population characteristics match those modelled	The use of generic preference-based instrument (preferably EQ-5D)	Change in HRQoL undertaken directly from the patients	Valuation of changes undertaken from general population	Choice-based methods used to value the health states
Spiraki 2008 ⁷¹	Y	N	N	N	U	N	N	U	Y	Y	Y	Y	N	Y
Squire 2017 ⁷²	Y	U	NA	NA	NA	N	N	U	Y	Y	Y	Y	Y	Y
Srinonprasert 2019 ⁷³	NA	NA	NA	NA	NA	N	N	U	Y	U	Y	Y	Y	Y
Stewart 2009 ⁷⁴	Y	N	NA	NA	NA	N	N	U	Y	Y	N	Y	N	Y
Stewart 2012 ⁷⁵	Y	U	Y	N	N	N	N	U	Y	Y	Y	Y	Y	Y
Stewart 2016 ⁷⁶	Y	N	Y	N	N	N	N	U	Y	Y	Y	Y	N	Y
Stromberg 2008 ⁷⁷	Y	N	Y	N	N	N	N	U	Y	Y	Y	Y	N	Y
Sullivan 2006 ⁷⁸	N	U	NA	NA	NA	N	N	U	Y	Y	Y	Y	Y	Y
Sullivan 2007 ⁷⁹	Y	U	Y	N	U	Y	N	N	Y	Y	N	Y	N	Y
Swinburn 2013 ⁸⁰	N	U	N	N	U	N	N	U	Y	Y	Y	N	Y	Y
Teng 2018 ⁸¹	N	U	Y	N	N	N	N	U	Y	N	Y	Y	N	Y
Thylen 2014 ⁸²	Y	U	NA	NA	NA	N	N	U	Y	Y	Y	Y	N	Y
van der Berg 2012 ⁸³	Y	U	NA	NA	NA	Y	N	N	Y	Y	Y	Y	N	Y
Van Spall 2019 ⁸⁴	U	U	N	N	U	N	N	U	Y	Y	Y	Y	N	Y
Vicent 2017 ⁸⁵	Y	U	NA	NA	NA	Y	N	N	Y	Y	Y	Y	N	Y
Wexler 2006 ⁸⁶	Y	U	NA	NA	NA	Y	Y	N	Y	Y	Y	Y	N	Y
Whitty 2013 ⁸⁷	Y	N	NA	NA	NA	N	Y	U	Y	N	Y	Y	N	Y
Yi 2004 ⁸⁸	Y	U	NA	NA	NA	N	N	U	Y	Y	N	N	N	Y
Zanaboni 2013 ⁸⁹	N	U	Y	Y	U	Y	Y	N	Y	Y	Y	Y	N	Y
Zhang 2012 ⁹⁰	Y	U	N	N	U	N	Y	U	Y	Y	Y	Y	Y	Y

Author and publication year	Response rates reported	Response rates likely threat to validity	Reported loss to follow-up	Reasons for the loss to follow-up given	Reasons for the loss to follow-up threat to the validity	Missing data reported	Methods to deal with missing data given	Missing data threat to the validity	Country patients match those modelled	Population characteristics match those modelled	The use of generic preference-based instrument (preferably EQ-5D)	Change in HRQoL undertaken directly from the patients	Valuation of changes undertaken from general population	Choice-based methods used to value the health states
Zugck 2014 ⁹¹	Y	U	N	N	U	Y	N	U	Y	Y	Y	Y	N	Y

Key

Higher quality	
Lower quality	
Not applicable	
Unclear	

References

1. Alehagen U, Rahmqvist M, Paulsson T, Levin L-Å. Quality-adjusted life year weights among elderly patients with heart failure. *Eur J Heart Fail* 2008;10(10):1033-1039.
2. Alva M, Gray A, Mihaylova B, Clarke P. The effect of diabetes complications on health-related quality of life: The importance of longitudinal data to address patient heterogeneity. *Health Econ*. 2014;23(4):487-500.
3. Ambrosy AP, Hernandez AF, Armstrong PW, et al. The clinical course of health status and association with outcomes in patients hospitalized for heart failure: Insights from ASCEND-HF. *Eur J Heart Fail* 2016;18(3):306-313.
4. Andreae C, Strömberg A, Chung ML, Hjelm C, Årestedt K. Depressive Symptoms Moderate the Association Between Appetite and Health Status in Patients With Heart Failure. *J Cardiovasc Nurs*. 2018;33(2):E15-E20.
5. Austin J, Williams R, Ross L, Moseley L, Hutchison S. Randomised controlled trial of cardiac rehabilitation in elderly patients with heart failure. *Eur J Heart Fail* 2005;7(3 SPEC. ISS.):411-417.
6. Austin J, Williams WR, Ross L, Hutchison S. Five-year follow-up findings from a randomized controlled trial of cardiac rehabilitation for heart failure. *Eur J Cardiovasc Prev Rehabil*. 2008;15(2):162-167.

7. Austin J, Williams WR, Hutchison S. Multidisciplinary management of elderly patients with chronic heart failure: Five year outcome measures in death and survivor groups. *Eur J Cardiovasc Nurs*. 2009;8(1):34-39.
8. Berg J, Lindgren P, Nieuwlaat R, Bouin O, Crijns H. Factors determining utility measured with the EQ-5D in patients with atrial fibrillation. *Qual Life Res*. 2010;1-10.
9. Berg J, Lindgren P, Mejhert M, Edner M, Dahlström U, Kahan T. Determinants of utility based on the EQ-5D in chronic heart failure patients and their change over time: Results from the Swedish heart failure registry. *Value Health*. 2015;18(3):A145.
10. Berg SK, Rasmussen TB, Thrysoee L, et al. DenHeart: Differences in physical and mental health across cardiac diagnoses at hospital discharge. *J Psychosomatic Res*. 2017;94:1-9.
11. Boros PW, Lubiński W. Health state and the quality of life in patients with chronic obstructive pulmonary disease in Poland: A study using the EQ-5D questionnaire. *Pol Arch Med Wewn*. 2012;122(3):73-81.
12. Briggs AH, Bhatt DL, Scirica BM, et al. Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. *Diabetes Res Clin Pract*. 2017;130:24-33.
13. Calvert MJ, Freemantle N, Cleland JGF. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. *Eur J Heart Fail* 2005;7(2):243-251.
14. Calvert MJ, Freemantle N, Yao G, et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. *Eur Heart J*. 2005;26(24):2681-2688.
15. Clark AL, Johnson M, Fairhurst C, et al. Does home oxygen therapy (HOT) in addition to standard care reduce disease severity and improve symptoms in people with chronic heart failure? A randomised trial of home oxygen therapy for patients with chronic heart failure. *Health Technol Assess*. 2015;19(75):1-120.
16. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). *Med Decis Making*. 2002;22(4):340-349.
17. Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. *Diabetes Care*. 2002;25(12):2238-2243.
18. Davies EW, Matza LS, Worth G, et al. Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysis. *Health Qual Life Outcomes*. 2015;13(1).
19. Delgado JF, Oliva J, Llano M, et al. Health care and nonhealth care costs in the treatment of patients with symptomatic chronic heart failure in Spain. *Rev Esp Cardiol (Engl Ed)*. 2014;67(8):643-650.

20. Emin A, Rogers CA, Banner NR, et al. Quality of life of advanced chronic heart failure: Medical care, mechanical circulatory support and transplantation. *Eur J Cardiothorac Surg*. 2016;50(2):269-273.
21. Eurich DT, Johnson JA, Reid KJ, Spertus JA. Assessing responsiveness of generic and specific health related quality of life measures in heart failure. *Health Qual Life Outcomes*. 2006;4:89.
22. Feeny D, Spritzer K, Hays RD, et al. Agreement about identifying patients who change over time: cautionary results in cataract and heart failure patients. *Med Decis Making*. 2012;32(2):273-286.
23. Feldman PH, Murtaugh CM, Pezzin LE, McDonald MV, Peng TR. Just-in-time evidence-based e-mail "reminders" in home health care: impact on patient outcomes. *Health Serv Res*. 2005;40(3):865-885.
24. Ferrer A, Formiga F, Cunillera O, et al. Predicting factors of health-related quality of life in octogenarians: a 3-year follow-up longitudinal study. *Qual Life Res*. 2015;24(11):2701-2711.
25. Filippatos G, Maggioni AP, Lam CSP, et al. Patient-reported outcomes in the SOLuble guanylate Cyclase stimulatOR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. *Eur J Heart Fail* 2017;19(6):782-791.
26. Göhler A, Geisler BP, Manne JM, et al. Utility estimates for decision-analytic modeling in chronic heart failure - Health states based on New York Heart Association classes and number of rehospitalizations. *Value Health*. 2009;12(1):185-187.
27. González-Guerrero JL, Hernández-Mocholi MA, Ribera-Casado JM, García-Mayolín N, Alonso-Fernández T, Gusi N. Cost-effectiveness of a follow-up program for older patients with heart failure: a randomized controlled trial. *Eur Geriatr Med*. 2018;9(4):523-532.
28. Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR, Sculpher M. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the U.K. National Health Service perspective. *Heart*. 2014;100(13):1031-1036.
29. Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR, Sculpher M. Analyzing Health-Related Quality of Life Data to Estimate Parameters for Cost-Effectiveness Models: An Example Using Longitudinal EQ-5D Data from the SHIFT Randomized Controlled Trial. *Adv Ther*. 2017;34(3):753-764.
30. Gutzwiller FS, Pfeil AM, Comin-Colet J, et al. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. *Int J Cardiol*. 2013;168(4):3878-3883.
31. Havranek EP, McGovern KM, Weinberger J, Brocato A, Lowes BD, Abraham WT. Patient preferences for heart failure treatment: Utilities are valid measures of health-related quality of life in heart failure. *J Card Fail*. 1999;5(2):85-91.
32. Havranek EP, Simon TA, L'Italien G, et al. The relationship between health perception and utility in heart failure patients in a clinical trial: Results from an OVERTURE substudy. *J Card Fail*. 2004;10(4):339-343.
33. Hayes A, Arima H, Woodward M, et al. Changes in quality of life associated with complications of diabetes: Results from the ADVANCE study. *Value Health*. 2016;19(1):36-41.

34. Hebert PL, Sisk JE, Wang JJ, et al. Cost-effectiveness of nurse-led disease management for heart failure in an ethnically diverse urban community. *Ann Intern Med.* 2008;149(8):540-548.
35. Holland R, Brooksby I, Lenaghan E, et al. Effectiveness of visits from community pharmacists for patients with heart failure: HeartMed randomised controlled trial. *BMJ.* 2007;334(7603):1098-1101.
36. Holland R, Rechel B, Stepien K, Harvey I, Brooksby I. Patients' Self-Assessed Functional Status in Heart Failure by New York Heart Association Class: A Prognostic Predictor of Hospitalizations, Quality of Life and Death. *J Card Fail.* 2010;16(2):150-156.
37. Holst M, Willenheimer R, Mårtensson J, Lindholm M, Strömberg A. Telephone follow-up of self-care behaviour after a single session education of patients with heart failure in primary health care. *Eur J Cardiovasc Nurs.* 2007;6(2):153-159.
38. Hwang R, Morris NR, Mandrusiak A, et al. Cost-Utility Analysis of Home-based Telerehabilitation Compared with Centre-based Rehabilitation in Patients with Heart Failure. *Heart Lung Circ.* 2018.
39. Iqbal J, Francis L, Reid J, Murray S, Denvir MA. Quality of life in patients with chronic heart failure and their carers: A 3-year follow-up study assessing hospitalisation and mortality. *Heart.* 2010;96:A41.
40. Jackson JDS, Cotton SE, Wirta SB, et al. Burden of heart failure on patients from China: results from a cross-sectional survey. *Drug Des Devel Ther.* 2018;12:1659-1668.
41. Janssen DJA, Franssen FME, Wouters EFM, Schols JMGA, Spruit MA. Impaired health status and care dependency in patients with advanced COPD or chronic heart failure. *Qual Life Res.* 2011;20(10):1679-1688.
42. Jolly K, Taylor RS, Lip GYH, et al. A randomized trial of the addition of home-based exercise to specialist heart failure nurse care: The Birmingham Rehabilitation Uptake Maximisation study for patients with Congestive Heart Failure (BRUM-CHF) study. *Eur J Heart Fail* 2009;11(2):205-213.
43. Kaplan RM, Tally S, Hays RD, et al. Five preference-based indexes in cataract and heart failure patients were not equally responsive to change. *J Clin Epidemiol.* 2011;64(5):497-506.
44. Kavanagh T, Myers MG, Baigrie RS, Mertens DJ, Sawyer P, Shephard RJ. Quality of life and cardiorespiratory function in chronic heart failure: Effects of 12 months' aerobic training. *Heart.* 1996;76(1):42-49.
45. Kimura M, Nawata K, Kinoshita O, et al. Readmissions after continuous flow left ventricular assist device implantation. *J Artif Organs.* 2017;20(4):311-317.
46. Kirsch J, McGuire A. Establishing health state valuations for disease specific states: An example from heart disease. *Health Economics.* 2000;9(2):149-158.
47. Kontodimopoulos N, Argiriou M, Theakos N, Niakas D. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure. *Eur J Health Econ.* 2011;12(4):383-391.

48. Kraai IH, Vermeulen KM, Luttik MLA, Hoekstra T, Jaarsma T, Hillege HL. Preferences of heart failure patients in daily clinical practice: Quality of life or longevity? *Eur J Heart Fail* 2013;15(10):1113-1121.
49. Kularatna S, Byrnes J, Chan YK, Carrington MJ, Stewart S, Scuffham PA. Comparison of contemporaneous responses for EQ-5D-3L and Minnesota Living with Heart Failure; a case for disease specific multiattribute utility instrument in cardiovascular conditions. *Int J Cardiol.* 2017;227:172-176.
50. Lewis EF, Johnson PA, Johnson W, Collins C, Griffin L, Stevenson LW. Preferences for quality of life or survival expressed by patients with heart failure. *J Heart Lung Transplant.* 2001;20(9):1016-1024.
51. Lewis EF, Li Y, Pfeffer MA, et al. Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction. A VALIANT Study (Valsartan in acute myocardial infarction). *JACC Heart Fail.* 2014;2(2):159-165.
52. Li Y, Neilson MP, Whellan DJ, Schulman KA, Levy WC, Reed SD. Associations between seattle heart failure model scores and health utilities: Findings from HF-ACTION. *J Card Fail.* 2013;19(5):311-316.
53. Luo X, Cappelleri JC, Chandran A. The burden of fibromyalgia: Assessment of health status using the EuroQol (EQ-5D) in patients with fibromyalgia relative to other chronic conditions. *Health Outcomes Research in Medicine.* 2011;2(4):e203-e214.
54. Matza LS, Stewart KD, Gandra SR, et al. Acute and chronic impact of cardiovascular events on health state utilities. *BMC Health Serv Res.* 2015;15:173.
55. Maxwell CJ, Kang J, Walker JD, et al. Sex differences in the relative contribution of social and clinical factors to the health utilities index mark 2 measure of health-related quality of life in older home care clients. *Health Qual Life Outcomes.* 2009;7:80.
56. Mondor L, Maxwell CJ, Bronskill SE, Gruneir A, Wodchis WP. The relative impact of chronic conditions and multimorbidity on health-related quality of life in Ontario long-stay home care clients. *Qual Life Res.* 2016;25(10):2619-2632.
57. Moskowitz AJ, Weinberg AD, Oz MC, Williams DL. Quality of life with an implanted left ventricular assist device. *Ann Thorac Surg.* 1997;64(6):1764-1769.
58. Muggah E, Graves E, Bennett C, Manuel DG. Ascertainment of chronic diseases using population health data: a comparison of health administrative data and patient self-report. *BMC Public Health.* 2013;13:16.
59. Nauck MA, Buse JB, Mann JFE, et al. Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. *Diabetes Obes Metab.* 2019;21(3):525-532.
60. Noyes K, Corona E, Veazie P, Dick AW, Zhao H, Moss AJ. Examination of the effect of implantable cardioverter-defibrillators on health-related quality of life: based on results from the Multicenter Automatic Defibrillator Trial-II. *Am J Cardiovasc Drugs.* 2009;9(6):393-400.
61. Peters M, Crocker H, Jenkinson C, Doll H, Fitzpatrick R. The routine collection of patient-reported outcome measures (PROMs) for long-term conditions in primary care: A cohort survey. *BMJ Open.* 2014;4(2): e003968
62. Pickard AS, Tawk R, Shaw JW. The effect of chronic conditions on stated preferences for health. *Eur J Health Econ.* 2013;14(4):697-702.

63. Pisa G, Eichmann F, Hupfer S. Assessing patient preferences in heart failure using conjoint methodology. *Patient Prefer Adherence*. 2015;9:1233-1241.
64. Pressler SJ, Eckert GJ, Morrison GC, Murray MD, Oldridge NB. Evaluation of the Health Utilities Index Mark-3 in heart failure. *J Card Fail*. 2011;17(2):143-150.
65. Reed SD, Kaul P, Li Y, et al. Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: Findings from ascend-HF. *J Card Fail*. 2013;19(9):611-620.
66. Roalfe AK, Bryant TL, Davies MH, et al. A cross-sectional study of quality of life in an elderly population (75 years and over) with atrial fibrillation: Secondary analysis of data from the Birmingham Atrial Fibrillation Treatment of the Aged study. *Europace*. 2012;14(10):1420-1427.
67. Sánchez JE, Ortega T, Rodríguez C, et al. Efficacy of peritoneal ultrafiltration in the treatment
68. Shao H, Yang S, Fonseca V, Stoecker C, Shi L. Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation. *Pharmacoeconomics*. 2019;37(7):921-929.
69. Shephard RJ, Kavanagh T, Mertens DJ. On the prediction of physiological and psychological responses to aerobic training in patients with stable congestive heart failure. *J Cardiopulm Rehabil*. 1998;18(1):45-51.
70. Spertus J, Peterson E, Conard MW, et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. *Am Heart J*. 2005;150(4):707-715.
71. Spiraki C, Kaitelidou D, Papakonstantinou V, Prezerakos P, Maniadakis N. Health-related quality of life measurement in patients admitted with coronary heart disease and heart failure to a cardiology department of a secondary urban hospital in Greece. *Hellenic J Cardiol*. 2008;49(4):241-247.
72. Squire L, Glover J, Corp J, Haroun R, Kuzan D, Gielen V. Impact of HF on HRQoL in patients and their caregivers in England: Results from the ASSESS study. *Br J Cardiol*. 2017;24(1):30-34.
73. Srinonprasert V, Ratanasumawong K, Thongsri T, et al. Factors associated with low health-related quality of life among younger and older Thai patients with non-valvular atrial fibrillation. *Qual Life Res*. 2019;28(8):2091-2098.
74. Stewart GC, Brooks K, Pratibhu PP, et al. Thresholds of Physical Activity and Life Expectancy for Patients Considering Destination Ventricular Assist Devices. *J Heart Lung Transplant*. 2009;28(9):863-869.
75. Stewart S, Carrington MJ, Marwick TH, et al. Impact of home versus clinic-based management of chronic heart failure: the WHICH? (Which Heart Failure Intervention Is Most Cost-Effective & Consumer Friendly in Reducing Hospital Care) multicenter, randomized trial. *J Am Coll Cardiol*. 2012;60(14):1239-1248.
76. Stewart GC, Kittleson MM, Patel PC, et al. INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure. *Circ Heart Fail*. 2016;9(11).
77. Strömberg A, Jaarsma T. Thoughts about death and perceived health status in elderly patients with heart failure. *Eur J Heart Fail* 2008;10(6):608-613.

78. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. *Med Decis Making*. 2006;26(4):410-420.
79. Sullivan MD, Levy WC, Russo JE, Crane B, Spertus JA. Summary Health Status Measures in Advanced Heart Failure: Relationship to Clinical Variables and Outcome. *J Card Fail*. 2007;13(7):560-568.
80. Swinburn P, Shingler S, Ong SH, Lecomte P, Lloyd A. Assessing the health-related quality of life in patients hospitalised for Acute heart failure. *Br J Cardiol*. 2013;20(2):72-76.
81. Teng H-C, Yeh M-L, Wang M-H. Walking with controlled breathing improves exercise tolerance, anxiety, and quality of life in heart failure patients: A randomized controlled trial. *Eur J Cardiovasc Nurs*. 2018;17(8):717-727.
82. Thylén I, Dekker RL, Jaarsma T, Strömberg A, Moser DK. Characteristics associated with anxiety, depressive symptoms, and quality-of-life in a large cohort of implantable cardioverter defibrillator recipients. *J Psychosomatic Res*. 2014;77(2):122-127.
83. Van Den Berg B. SF-6D population norms. *Health Econ*. 2012;21(12):1508-1512.
84. Van Spall HGC, Lee SF, Xie F, et al. Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure: The PACT-HF Randomized Clinical Trial. *JAMA*. 2019;321(8):753-761.
85. Vicent L, Nunez Olarte JM, Puente-Maestu L, et al. Degree of dyspnoea at admission and discharge in patients with heart failure and respiratory diseases. *Eur J Heart Fail* 2017;19:55-56.
86. Wexler DJ, Grant RW, Wittenberg E, et al. Correlates of health-related quality of life in type 2 diabetes. *Diabetologia*. 2006;49(7):1489-1497.
87. Whitty JA, Stewart S, Carrington MJ, et al. Patient Preferences and Willingness-To-Pay for a Home or Clinic Based Program of Chronic Heart Failure Management: Findings from the Which? Trial. *PLoS ONE*. 2013;8(3).
88. Yi MS, Luckhaupt S, Mrus JM, Tsevat J. Do medical house officers value the health of veterans differently from the health of non-veterans? *Health Qual Life Outcomes*. 2004;2.
89. Zanaboni P, Landolina M, Marzegalli M, et al. Cost-utility analysis of the EVOLVO study on remote monitoring for heart failure patients with implantable defibrillators: randomized controlled trial. *J Med Internet Res*. 2013;15(5):e106.
90. Zhang P, Brown MB, Bilik D, Ackermann RT, Li R, Herman WH. Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from Translating Research Into Action for Diabetes (TRIAD). *Diabetes Care*. 2012;35(11):2250-2256.
91. Zugck C, Martinka P, Stöckl G. Ivabradine Treatment in a Chronic Heart Failure Patient Cohort: Symptom Reduction and Improvement in Quality of Life in Clinical Practice. *Adv Ther*. 2014;31(9):961-974